Author

Alan G. Olivero

Observed names: A. G. OLIVERO, A. Olivero, A.G. Olivero, Alan G Olivero, Alan Olivero

Observed institutions: Mayo Clinic, Institute of Cancer Research, Genentech, Cancer Research UK, ETH Zurich, Laboratory of Organic Chemistry

OpenAlex ID: A5103885960

The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

2008 · Adrian J. Folkes, Khatereh Ahmadi, et al. · Journal of Medicinal Chemistry · 742

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

2011 · Jeffrey J. Wallin, Kyle A. Edgar, et al. · Molecular Cancer Therapeutics · 229

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

2011 · Daniel P. Sutherlin, Linda Bao, et al. · Journal of Medicinal Chemistry · 219

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

2013 · Chudi O. Ndubaku, Timothy P. Heffron, et al. · Journal of Medicinal Chemistry · 179

Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer

2010 · Daniel P. Sutherlin, Deepak Sampath, et al. · Journal of Medicinal Chemistry · 133

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR

2016 · Timothy P. Heffron, Chudi O. Ndubaku, et al. · ACS Medicinal Chemistry Letters · 110

PDF

The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of ( S )-2-((2-(1-Isopropyl-1 H -1,2,4-triazol-5-yl)-5,6-dihydrobenzo[ f ]imidazo[1,2- d ][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)

2016 · Timothy P. Heffron, Robert A. Heald, et al. · Journal of Medicinal Chemistry · 106

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

2020 · Patrick Y. Wen, Timothy F. Cloughesy, et al. · Clinical Cancer Research · 96

PDF

Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor

2010 · Timothy P. Heffron, Megan Berry, et al. · Bioorganic & Medicinal Chemistry Letters · 90

Selectivities in the Reactions of Alkyl‐, Aryl‐ and Heterosubstituted Organotitanium Compounds Preliminary Communication

1981 · Beat Weidmann, Leo Widler, et al. · Helvetica Chimica Acta · 90

Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier

2012 · Laurent Salphati, Timothy P. Heffron, et al. · Clinical Cancer Research · 70

Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform

2011 · Timothy P. Heffron, BinQing Wei, et al. · Journal of Medicinal Chemistry · 70

Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma

2019 · Sarah M. Bronner, Karl A. Merrick, et al. · Bioorganic & Medicinal Chemistry Letters · 66

Potent and selective pyrazole-based inhibitors of B-Raf kinase

2008 · Joshua D. Hansen, Jonas Grina, et al. · Bioorganic & Medicinal Chemistry Letters · 66

From Peptide to Non-Peptide. 3. Atropisomeric GPIIbIIIa Antagonists Containing the 3,4-Dihydro-1H-1,4-benzodiazepine-2,5-dione Nucleus

1997 · Brent K. Blackburn, Arthur Lee, et al. · Journal of Medicinal Chemistry · 59

The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase α

2012 · Timothy P. Heffron, Laurent Salphati, et al. · Journal of Medicinal Chemistry · 54

Enantioselective Addition of Chiral Organotitanium Derivatives to Aldehydes

1981 · Alan G. Olivero, Beat Weidmann, et al. · Helvetica Chimica Acta · 54

Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma

2016 · Laurent Salphati, Bruno Alicke, et al. · Drug Metabolism and Disposition · 52

Distribution of the Phosphatidylinositol 3-Kinase Inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 Intracranial Glioblastoma Models—Assessment by Matrix-Assisted Laser Desorption Ionization Imaging

2014 · Laurent Salphati, Sheerin Shahidi-Latham, et al. · Drug Metabolism and Disposition · 46

Non-oxime pyrazole based inhibitors of B-Raf kinase

2010 · Bradley J. Newhouse, Joshua D. Hansen, et al. · Bioorganic & Medicinal Chemistry Letters · 46

Inhibitors of Tissue Factor • Factor VIIa for Anticoagulant Therapy

2004 · Robert Lazarus, Alan Olivero, et al. · Current Medicinal Chemistry · 42

A Selective, Slow Binding Inhibitor of Factor VIIa Binds to a Nonstandard Active Site Conformation and Attenuates Thrombus Formation in Vivo

2005 · Alan G. Olivero, Charles Eigenbrot, et al. · Journal of Biological Chemistry · 41

Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human

2012 · Laurent Salphati, Jodie Pang, et al. · Drug Metabolism and Disposition · 37

Structure-based design of thienobenzoxepin inhibitors of PI3-kinase

2011 · Steven T. Staben, Michael Siu, et al. · Bioorganic & Medicinal Chemistry Letters · 37

Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase

2010 · Steven T. Staben, Timothy P. Heffron, et al. · Bioorganic & Medicinal Chemistry Letters · 29

Works count: 106

Citation count: 2,948

H-index: 26

I10-index: 33